Introducing a STAT consensus sequence in the oncolytic virus XVir-N-31 improves the therapeutic effect without interfering with the innate immune response (DGU 2026) - Oct 15, 2026 - Abstract #V23-05; Pres time: Sep 17, 2026; 03:51 PM - 04:00 PM; Location: Room 17; "JAK/STAT inhibitors were Ruxolitinib, Itacitinib, Static and Napabucasin and for gene silencing we enabled siRNAs/siTools against STAT-1,-3, and -5. JAK/STAT signaling prevents adenoviral replication by an E1A dependent mechanism that controls expression of E1B55k, E2 and E4. We developed a strategy to trap STAT molecules by cloning a multimerized STAT consensus sequence in the OAV XVir-N-31 resulting in improved therapeutic potency. Copyright : Roman Nawroth"
IO biomarker • Oncolytic virus • Bladder Cancer • Genito-urinary Cancer • Infectious Disease • Solid Tumor • STAT1
|
|
S. Nassua 1; D. Wang 1; J. Bambach 1; K. Mantwill 1; P.-S. Holm 1; J.E. Gschwend 1; R. Nawroth 1
|